Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000075661 | SCV000106663 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Coding variation introducing premature termination codon |
Department of Pathology and Laboratory Medicine, |
RCV001353809 | SCV000592353 | pathogenic | Carcinoma of colon | no assertion criteria provided | clinical testing | The p.Thr116GlnfsX20 variant has been reported in the literature in 8/1418 proband chromosomes with HNPCC. However, no control chromosomes were tested to establish the frequency of the variant in the general population (Casey 2005, Choi 2009). In one of these studies, the patient with the variant met the Amsterdam criteria and also showed loss of MLH1 protein expression (Casey 2005). The variant is listed in the dbSNP database as coming from a "clinical source" (ID#:rs63750906), but no frequency information was provided, and so the prevalence of this variant in the population is not known. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 116 and leads to a premature stop codon, 20 codons downstream. This alteration is then predicted to lead to a truncated or absent protein and loss of function. Loss of function variants are an established mechanism of disease for the MLH1 gene and is the type of alteration expected to cause the disorder. In summary, based on the above information, this variant is classified as pathogenic. |